Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant dendritic cell vaccine in resected stage IV NET and STS
2023-510251-31-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of DC-VACCINE IRST-IRCCS and aldesleukin in apudoma (NET) and soft tissue sarcoma (STS) (2 cohorts), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Safety - grade 3 or higher adverse events and Tumor antigen-specific immune response. Planned start Jul 2024; status: authorised.
02
Drugs
DC-VACCINE IRST-IRCCSaldesleukin
03
Conditions
apudoma (NET)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2023-510251-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510251-31-00.